Imfinzi

Imfinzi

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Durvalumab
Indications/Uses
Treatment of patients w/ locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy &/or have disease progression w/in 12 mth of neoadjuvant or adjuvant treatment w/ platinum-containing chemotherapy. Treatment of patients w/ unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy & radiation therapy.
Dosage/Direction for Use
Urothelial carcinoma 10 mg/kg IV infusion over 60 min every 2 wk, until disease progression or unacceptable toxicity. NSCLC 10 mg/kg IV infusion over 60 min every 2 wk, until disease progression, unacceptable toxicity, or a max of 12 mth.
Special Precautions
Monitor patients for signs & symptoms of pneumonitis; hepatitis; colitis or diarrhea; thyroid disorders, adrenal insufficiency, type 1 DM, hypophysitis/hypopituitarism; rash; infection; infusion-related reactions. Can cause other severe & fatal immune-related adverse reactions. Monitor patients for abnormal renal function tests prior to & periodically during treatment. Can cause fetal harm. Women of childbearing potential should use effective contraception during therapy & for at least 3 mth after the last dose. Pregnancy & lactation. Elderly ≥75 yr. Childn.
Adverse Reactions
Very common (≥15%) in urothelial carcinoma: Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, UTI. Very common (≥20%) in NSCLC: Cough, fatigue, pneumonitis/radiation pneumonitis, upper resp tract infections, dyspnea, rash.
ATC Classification
L01XC28 - durvalumab ; Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Imfinzi concentrate for soln for infusion 120 mg/2.4 mL
Packing/Price
1's
Form
Imfinzi concentrate for soln for infusion 500 mg/10 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in